Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Dana-Farber Cancer Institute
Study ID
NCT00131014
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Study Details

The purpose of this study is to investigate possible genetic factors that contribute to the development of lymphomas. The databank will be used to determine whether familial lymphomas have unique genetic characteristics different from sporadic lymphomas and to attempt to identify a gene that confers an increased risk of lymphoma.

Key Dates

Start date
Aug 9, 2004
Status verified
Apr 2026
Primary completion
Jan 31, 2033
Completion
Jan 31, 2033

Study Design

Enrollment
1,500 participants (estimated)

Arms

  • Arm: Next of Kin of deceased subj by lymphoma
    Next of Kin of deceased subject by lymphoma
  • Arm: Subject unaffected by lymphoma
    Subject unaffected by lymphoma
  • Arm: Subject affected by lymphoma
    Subject affected by lymphoma

Primary Outcome Measure

Genetic factors that contribute to the development of lymphomas and CLL [ Time Frame: Indefinite ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Dana-Farber Cancer InstituteBostonMassachusetts02115
Jennifer R. Brown, MD, PhD
[email protected]
617-632-6692
Jennifer R. Brown, MD, PhD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Boston, MA

By research site
Dana-Farber Cancer Institute· Boston, MA

Related Studies